Literature DB >> 15547709

Evaluation of metastatic potential in prostate carcinoma: an in vivo model.

Adriano Angelucci1, Giovanni Luca Gravina, Nadia Rucci, Claudio Festuccia, Paola Muzi, Carlo Vicentini, Anna Teti, Mauro Bologna.   

Abstract

Prostate cancer is frequently associated with bone metastases, which are in fact the main cause of morbidity and mortality for this tumor. To better investigate this process, animal models of bone and bone marrow metastases need to be developed. However, experimental prostate cancer bone metastases are difficult to be obtained in vivo, and some typical clinical patterns remain irreproducible. In this study, we injected PC3 prostate cancer cells into the left cardiac ventricle of nude mice, thus reproducing the basic biological phenomenon of tumor cell spreading in the arterious blood stream, and compared the outcome with direct injection of cells in the bone marrow cavity of the tibia. Mice were monitored by X-ray analysis. After 40 days, 100% of intratibially-injected and 64% of heart-injected mice revealed osteolytic lesions. The heart injection was then used to select PC3 cell subpopulations by serial inoculation and recovery from bone metastasis. One of the resulting cell populations, obtained by a second round of selection and denominated PCb2, showed a more invasive phenotype compared to parental PC3, both in vitro and in vivo. Although PCb2 cells had a growth rate comparable to that of PC3 cells, they generated a higher number of bone lesions in nude mice and crossed more easily the Matrigel barrier in vitro in the presence of several chemoattractants. This phenomenon was partially due to an increased capacity to adhere to laminin and to release MMP-2 at higher level relative to the original PC3 cells. This study demonstrates that heart injection of prostate cancer cells in nude mice may represent a good experimental model to investigate the pathophysiology of bone and bone marrow metastases in vivo.

Entities:  

Mesh:

Year:  2004        PMID: 15547709

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Non-invasive microCT imaging characterization and in vivo targeting of BB2 receptor expression of a PC-3 bone metastasis model.

Authors:  Christopher T Winkelmann; Said Daibes Figueroa; Gary L Sieckman; Tammy L Rold; Timothy J Hoffman
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

2.  Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.

Authors:  Prasenjit Dey; Philip Jonsson; Johan Hartman; Cecilia Williams; Anders Ström; Jan-Åke Gustafsson
Journal:  Mol Endocrinol       Date:  2012-10-01

3.  Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging.

Authors:  Justin M Drake; Curtis L Gabriel; Michael D Henry
Journal:  Clin Exp Metastasis       Date:  2006-05-16       Impact factor: 5.150

4.  EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts.

Authors:  Elisa Giannoni; Maria Letizia Taddei; Matteo Parri; Francesca Bianchini; Michela Santosuosso; Renata Grifantini; Gabriella Fibbi; Benedetta Mazzanti; Lido Calorini; Paola Chiarugi
Journal:  J Mol Med (Berl)       Date:  2012-08-19       Impact factor: 4.599

5.  Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.

Authors:  Maria Letizia Taddei; Matteo Parri; Adriano Angelucci; Barbara Onnis; Francesca Bianchini; Elisa Giannoni; Giovanni Raugei; Lido Calorini; Nadia Rucci; Anna Teti; Mauro Bologna; Paola Chiarugi
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

6.  CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis.

Authors:  Véronique Ouellet; Peter M Siegel
Journal:  J Cell Commun Signal       Date:  2012-03-18       Impact factor: 5.782

7.  KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Patrizia Sanita; Flora Vitale; Francesco Marampon; Luca Ventura; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Claudio Festuccia
Journal:  BMC Cancer       Date:  2015-12-01       Impact factor: 4.430

Review 8.  Prostate cancer and bone: the elective affinities.

Authors:  Nadia Rucci; Adriano Angelucci
Journal:  Biomed Res Int       Date:  2014-05-28       Impact factor: 3.411

9.  XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).

Authors:  Giovanni Luca Gravina; Monica Tortoreto; Andrea Mancini; Alessandro Addis; Ernesto Di Cesare; Andrea Lenzi; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Nadia Zaffaroni; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2014-10-05       Impact factor: 17.388

10.  Basigin-2 upregulated by receptor activator of NF-κB ligand enhances lung cancer-induced osteolytic lesions.

Authors:  Cheng-Gong Liao; Li Yao; Wei Xie; Lili Liu; Sheng-Da Wu; Ning Lu; Jian-Guo Huang; Ling-Min Kong; He-Long Zhang
Journal:  Cancer Cell Int       Date:  2016-04-02       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.